Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Jun 2;4(3):100508.
doi: 10.1016/j.jacig.2025.100508. eCollection 2025 Aug.

Successful management of Netherton syndrome using IVIG and dupilumab: A case report

Affiliations
Case Reports

Successful management of Netherton syndrome using IVIG and dupilumab: A case report

Reshale Johar et al. J Allergy Clin Immunol Glob. .

Abstract

Netherton syndrome (NS) is a rare autosomal recessive genodermatosis caused by pathogenic mutations in the serine protease inhibitor Kazal-type 5 (SPINK5) gene, leading to impaired skin barrier function and immune dysregulation. It is characterized by congenital ichthyosis, trichorrhexis invaginata, and severe atopy. Herein, we present the case of a young boy with NS, confirmed by genetic analysis revealing a homozygous splice site mutation in SPINK5 (c.1302+5G>C). The patient was treated with intravenous immunoglobulin due to frequent infections that required multiple hospital admissions. When he was 6 years old, dupilumab was added to reduce skin inflammation and improve skin barrier function before food reintroduction. He demonstrated substantial clinical benefits, with marked relief from pruritus resulting in better quality of life. Additionally, he exhibited notable hair growth. Serologically, total his serum IgE levels decreased from 1078 IU/mL to 55.8 IU/mL following dupilumab therapy. This case highlights the potential benefits of an integrated therapeutic approach in management of this challenging condition.

Keywords: IVIG; Netherton syndrome; SPINK5; bamboo hair; dupilumab; food allergy; trichorrhexis invaginata.

PubMed Disclaimer

Conflict of interest statement

Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.

Figures

Fig 1
Fig 1
A, Generalized erythroderma at birth. B, Thick scaly plaques over the scalp with persistent erythema and sparse hair. C and D, Recurrent skin infections at age of 6 months. E, Resolution of erythema and scale with hair regrowth after 1 year of IVIG and food elimination. F, Significant resolution of skin lesions and reduction of itch after 5 years of IVIG and food elimination, along with 2 years of dupilumab therapy.

Similar articles

References

    1. Barbati F., Giovannini M., Oranges T., Lodi L., Barni S., Novembre E., et al. Netherton syndrome in children: management and future perspectives. Front Pediatr. 2021;9 - PMC - PubMed
    1. Chavanas S., Bodemer C., Rochat A., Hamel-Teillac D., Ali M., Irvine A.D., et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet. 2000;25 - PubMed
    1. Chiticariu E., Hohl D. Netherton syndrome: insights into pathogenesis and clinical implications. J Invest Dermatol. 2020;140:1129–1130. - PubMed
    1. Boskabadi H., Maamouri G., Mafinejad S. Netherton syndrome, a case report and review of literature. Iran J Pediatr. 2013;23:611–612. - PMC - PubMed
    1. Guerra L., Fortugno P., Pedicelli C., Mazzanti C., Proto V., Zambruno G., Castiglia D. Ichthyosis linearis circumflexa as the only clinical manifestation of Netherton syndrome. Acta Derm Venereol. 2015;95:720–724. - PubMed

Publication types

LinkOut - more resources